Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H28N4O6S2 |
Molecular Weight | 472.579 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)CSC(NC(C)C)=NC(C)C)C(O)=O
InChI
InChIKey=JYXACOFERDBGGQ-RHSMWYFYSA-N
InChI=1S/C19H28N4O6S2/c1-9(2)20-19(21-10(3)4)31-8-13(25)22-14-16(26)23-15(18(27)28)12(6-29-11(5)24)7-30-17(14)23/h9-10,14,17H,6-8H2,1-5H3,(H,20,21)(H,22,25)(H,27,28)/t14-,17-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/28384434Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/14761333 | https://www.ncbi.nlm.nih.gov/pubmed/3104591 | https://www.ncbi.nlm.nih.gov/pubmed/25499488
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28384434
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/14761333 | https://www.ncbi.nlm.nih.gov/pubmed/3104591 | https://www.ncbi.nlm.nih.gov/pubmed/25499488
Cefathiamidine is a beta-lactam antibiotic that exhibits a broad spectrum of bactericidal activity against gram-positive bacteria. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3104591 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Xianlisu Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28384434
1000mg cefathiamidine intramuscularly
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3104591
S . faecalis NCTC 775, S . faecium NCTC 7171 and a highly beta-lactam-resistant clinical isolate of S . faecium, strain 37, were used. MICs were determined in Antibiotic Medium 3 (Bacto-penassay broth, Difco) by the broth dilution method. The susceptibility to each of penicillin, ciprofloxacin, spectinomycin and azithromycin was interpreted according to the World Health Organization (WHO) Western Pacific Region Program criteria (Cefathiamidine MIC=2mg/L)
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000127416
Created by
admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
|
PRIMARY | |||
|
C018866
Created by
admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
|
PRIMARY | |||
|
DTXSID60954696
Created by
admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
|
PRIMARY | |||
|
15942748
Created by
admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
|
PRIMARY | |||
|
8M7CAS5T8L
Created by
admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
|
PRIMARY | |||
|
SUB33452
Created by
admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
|
PRIMARY | |||
|
5168
Created by
admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
|
PRIMARY | |||
|
33075-00-2
Created by
admin on Sat Dec 16 06:39:21 GMT 2023 , Edited by admin on Sat Dec 16 06:39:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY